· Regulation · Regulation Desk
National coverage of the PCAC vote blurred bulks list eligibility with drug approval. This explainer separates the two, names the six recommended peptides, and sets out the rulemaking steps still ahead.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.